Literature DB >> 32516028

NOD2 in hepatocytes engages a liver-gut axis to protect against steatosis, fibrosis, and gut dysbiosis during fatty liver disease in mice.

Joseph F Cavallari1, Nenad T Pokrajac1, Soumaya Zlitni2, Kevin P Foley1, Brandyn D Henriksbo1, Jonathan D Schertzer1.   

Abstract

Obesity promotes non-alcoholic fatty liver disease (NAFLD). The intestinal microbiota contributes to NAFLD progression through a gut to liver pathway that promotes inflammation and fibrosis. Gut microbiota-derived factors can travel to the liver and activate immune responses in liver-resident cells to promote inflammation and NAFLD. Little is known about bacterial sensors or immune responses that can protect against NAFLD. We tested if the bacterial cell wall sensor nucleotide-binding oligomerization domain-containing (NOD)2 protects against diet-induced NAFLD in mice. Whole-body deletion of NOD2 exacerbated liver steatosis and fibrosis in mice fed a NAFLD-promoting diet. Mice with a hepatocyte-specific deletion of NOD2 (Nod2-/-HKO) also had higher liver steatosis and fibrosis compared to littermate wild type mice (WTloxp) fed a NAFLD-promoting diet. Hepatocyte-specific NOD2 deletion altered the composition of the gut microbiome. Nod2-/-HKO mice had increased relative abundance of Clostridiales and lower Erysipelotrichaceae among other changes in cecal bacteria compared to littermate WTloxp mice. Hepatocyte-specific NOD2 deletion altered a transcriptional program of liver inflammation, metabolism, and fibrosis. Nod2-/-HKO mice had higher levels of transcripts involved in lipid and cholesterol metabolism. Nod2-/-HKO mice had higher transcript levels of transforming growth factor beta and collagen isoforms, which coincided with higher levels of liver collagen compared to WTloxp mice. These data show that bacterial cell wall sensing within hepatocytes can engage retrograde crosstalk from the liver to the gut, where liver immunity communicates with the gut to influence the intestinal host-microbe relationship during diet-induced NAFLD, and NOD2 within the hepatocyte confers protection from liver steatosis and fibrosis.

Entities:  

Keywords:  gut; inflammation; microbiome; microbiota; obesity

Year:  2020        PMID: 32516028     DOI: 10.1152/ajpendo.00181.2020

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  10 in total

1.  Peripheral and central regulation of insulin by the intestine and microbiome.

Authors:  Jonathan D Schertzer; Tony K T Lam
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-12-14       Impact factor: 4.310

2.  Insulin resistance corresponds with a progressive increase in NOD1 in high fat diet-fed mice.

Authors:  Aditya Sharma; Sushmita Singh; Alok Mishra; Amit K Rai; Ishbal Ahmad; Shadab Ahmad; Farah Gulzar; Jonathan D Schertzer; Ashutosh Shrivastava; Akhilesh K Tamrakar
Journal:  Endocrine       Date:  2022-02-02       Impact factor: 3.633

Review 3.  Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.

Authors:  Si-Nan Lin; Ren Mao; Chenchen Qian; Dominik Bettenworth; Jie Wang; Jiannan Li; David H Bruining; Vipul Jairath; Brian G Feagan; Min-Hu Chen; Florian Rieder
Journal:  Physiol Rev       Date:  2021-09-27       Impact factor: 37.312

Review 4.  Mediators of Metabolism: An Unconventional Role for NOD1 and NOD2.

Authors:  Megan T Zangara; Isabel Johnston; Erin E Johnson; Christine McDonald
Journal:  Int J Mol Sci       Date:  2021-01-25       Impact factor: 5.923

Review 5.  The Gut Microbial Endocrine Organ in Type 2 Diabetes.

Authors:  William Massey; J Mark Brown
Journal:  Endocrinology       Date:  2021-02-01       Impact factor: 4.736

Review 6.  Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis.

Authors:  Julio Plaza-Díaz; Patricio Solis-Urra; Jerónimo Aragón-Vela; Fernando Rodríguez-Rodríguez; Jorge Olivares-Arancibia; Ana I Álvarez-Mercado
Journal:  Biomedicines       Date:  2021-02-03

Review 7.  Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment.

Authors:  Leen J M Heyens; Dana Busschots; Ger H Koek; Geert Robaeys; Sven Francque
Journal:  Front Med (Lausanne)       Date:  2021-04-14

Review 8.  Activation of NOD1 and NOD2 in the development of liver injury and cancer.

Authors:  Naoya Omaru; Tomohiro Watanabe; Ken Kamata; Kosuke Minaga; Masatoshi Kudo
Journal:  Front Immunol       Date:  2022-10-04       Impact factor: 8.786

9.  Bacterial Postbiotics as Promising Tools to Mitigate Cardiometabolic Diseases.

Authors:  Fernando F Anhê; Benjamin A H Jensen; Lais Rossi Perazza; André Tchernof; Jonathan D Schertzer; André Marette
Journal:  J Lipid Atheroscler       Date:  2021-02-09

Review 10.  Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.

Authors:  Natalia Vallianou; Gerasimos Socrates Christodoulatos; Irene Karampela; Dimitrios Tsilingiris; Faidon Magkos; Theodora Stratigou; Dimitris Kounatidis; Maria Dalamaga
Journal:  Biomolecules       Date:  2021-12-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.